Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 223014, Berlin

Institut Paoli-Calmettes /ID# 222307, Marseille

Universitaetsklinikum Hamburg-Eppendorf /ID# 222258, Hamburg

Duke University Medical Center /ID# 222166, Durham

Duplicate_Emory University, Winship Cancer Institute /ID# 222922, Atlanta

Norton Healthcare Pavilion /ID# 222918, Louisville

CHU de Nantes, Hotel Dieu -HME /ID# 222303, Nantes

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 223839, Meldola

Duplicate_Universitaetsklinikum Muenster /ID# 222504, Münster

Duplicate_Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 222372, Mainz

CHRU Lille - Hopital Claude Huriez /ID# 222302, Lille

HCL - Hopital Lyon Sud /ID# 222304, Pierre-Bénite

Institut Gustave Roussy /ID# 223951, Villejuif

Dana-Farber Cancer Institute /ID# 222174, Boston

University of Texas Southwestern Medical Center /ID# 223811, Dallas

Duplicate_Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita /ID# 223224, Rome

Nagoya City University Hospital /ID# 222408, Nagoya

National Cancer Center Hospital East /ID# 239436, Kashiwa-shi

Hospital Duran i Reynals /ID# 222329, L'Hospitalet de Llobregat